Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicentre randomized Trial

Next Previous
Trial Profile

Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicentre randomized Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Liver failure
  • Focus Therapeutic Use
  • Acronyms GRAFT

Most Recent Events

  • 05 Aug 2021 Primary endpoint (Transplant-free survival at 90 days, defined as time from randomization to death or OLT, censoring patients alive without OLT at the date of last information.) has not been met. according to the results published in the Journal of Hepatology.
  • 05 Aug 2021 Results published in the Journal of Hepatology
  • 13 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top